Table 3 Relation between patient RECIST 1.1 response and results of HER2 PET/CT, early FDG PET/CT and their combination.
A | Patient-based analysis of the “complete” cohort (n = 90) | |||||
|---|---|---|---|---|---|---|
Classification | n patients | RECIST 1.1 after three T-DM1 cycles | PPV | NPV | ||
R | NR | |||||
HER2 PET/CT | + | 53 | 41 | 12 | 77%1 | |
− | 25 | 4 | 21 | 84%2 | ||
Early FDG PET/CT | R | 42 | 40 | 2 | 95%3 | |
NR | 37 | 6 | 31 | 84%4 | ||
HER2 PET/CT/Early FDG PET/CT | +/R | 36 | 36 | 0 | 100% | |
+/NR | 17 | 5 | 12 | |||
−/R | 6 | 4 | 2 | |||
−/NR | 19 | 0 | 19 | 100% | ||
B | Subgroup patient-based analysis of the “expansion” cohort (n = 30) | |||||
Classification | n patients | RECIST 1.1 after three T-DM1 cycles | PPV | NPV | ||
R | NR | |||||
HER2 PET/CT | + | 14 | 13 | 1 | 93%1 | |
− | 9 | 2 | 7 | 78%2 | ||
Early FDG PET/CT | R | 15 | 14 | 1 | 93%3 | |
NR | 8 | 1 | 7 | 88%4 | ||
HER2 PET/CT/Early FDG PET/CT | +/R | 12 | 12 | 0 | 100% | |
+/NR | 2 | 1 | 1 | |||
−/R | 3 | 2 | 1 | |||
−/NR | 6 | 0 | 6 | 100% | ||
